Background-Long-term data on device-related untoward events in patients receiving defibrillators for resynchronization therapy (CRT-D) are lacking. We quantified the frequency of repeat invasive procedures and the nature of long-term complications in current clinical practice and examined possible predictors of device-related events and their association with long-term patient outcome. Methods and Results-We analyzed data from 3253 patients who underwent de novo successful implantation of CRT-D and were followed up for a median of 18 months (25th to 75th percentiles: 9 to 30) in 117 Italian centers. Device-related events were reported in 416 patients, and, specifically, surgical interventions for system revision were described in 390 patients. Four years after the implantation procedure, 50% of patients underwent surgical revision for battery depletion and 14% for unanticipated events. For comparison, at 4 years battery depletion occurred in 10% and 13% of patients who received single-and dual-chamber defibrillators at the study centers, and unanticipated events were reported as 4% and 9%, respectively. In CRT-D, infections occurred at a rate of 1.0%/y, and the risk of infections increased after device replacement procedures (hazard ratio, 2.04; 95% confidence interval, 1.01 to 4.09; Pϭ0.045). Left ventricular lead dislodgements were reported at a rate of 2.3%/y and were predicted by longer fluoroscopy time and higher pacing threshold on implantation. Device-related events were not associated with a worse clinical outcome; indeed, the risk of death was similar in patients with and without surgical revision (hazard ratio, 0.90; 95% confidence interval, 0.56 to 1.47; Pϭ0.682). Conclusions-In current clinical practice device-related events are more frequent in CRT-D than in single-or dual-chamber defibrillators, and are frequently managed by surgical intervention for system revision. However, a worse clinical outcome is not seem to be associated with these events. Clinical Trial Registration-URL: http://clinicaltrials.gov. Unique identifier: NCT01007474.
cialty and certification, 7, 8 and hospital implantation volume. 9 However, the vast majority of reports refer to periprocedural adverse events or early complications and describe their association only with short-term patient outcome.
By contrast, long-term data on the burden of device-related untoward events in patients receiving CRT-D are lacking. Although long-term data have been published with regard to the loss of CRT in patients enrolled in earlier CRT-D studies 10 or complications in single-center series, 11 no data from large-scale databases on current clinical practice have been reported. We therefore sought to quantify the frequency of repeat invasive procedures and the nature of long-term complications after CRT-D implantation in general practice, and to examine predictors of device-related events and their association with long-term patient outcome.
Methods

Patient Population and Study Procedures
Patients who underwent successful implantation of a CRT-D system were included consecutively by the cardiovascular centers that participate in the Italian ClinicalService project, a national medical care project that started in 2004 and with the mission of evaluating and improving the use of implantable cardiac devices in clinical practice. The project consists of a shared environment for the collection, management, analysis, and reporting of clinical and diagnostics data from patients wearing Medtronic (Minneapolis, MN) implantable devices. These data are prospectively collected and may be mined to perform observational research. An independent physician steering committee prospectively identifies key clinical questions on a yearly basis for analysis and publication. A charter assigns the ownership of data to the centers and governs the conduct of and relationship between the steering committee and Medtronic personnel.
Each patient signed an informed consent form, which had been approved by the Institutional Review Board of each center. All patients underwent biventricular ICD placement with transvenous implantation of a right ventricular defibrillation lead, an atrial pacing lead (except for patients in permanent atrial fibrillation), and a coronary sinus lead for left ventricular (LV) pacing (Medtronic) in accordance with current guidelines 2, 5 (ie, advanced heart failure [NYHA class II, III, or IV], depressed LV function [LV ejection fraction Յ35%], and wide QRS complex [Ն120 ms]).
For the aims of the present study, we considered patients who underwent de novo CRT-D implantation. We included in analysis patients with preexisting single-or dual-chamber pacemakers and excluded patients who underwent replacement of a CRT device (pacemaker or ICD) or upgraded from a previous ICD to CRT-D.
Baseline assessment comprised the collection of demographic data and medical history, clinical examination, 12-lead ECG, estimation of NYHA functional class, and echocardiographic evaluation. Inhospital follow-up examinations were scheduled according to the clinical practice of each center. Clinical management was performed at the discretion of expert cardiologists. Implantable cardioverterdefibrillators were programmed in accordance with the clinical practice of each center. At each scheduled or unscheduled visit, the CRT-D was interrogated, and the integrity and appropriate functioning of the implanted system was checked. Information on clinical outcomes, such as hospitalizations and deaths, was collected during hospital visits or, if patients missed scheduled visits, via telephone calls.
We determined the annual volume of activity at each hospital on the basis of data from the National ICD Registry of the Italian Society of Arrhythmology and Cardiac Pacing (AIAC). 12 Specifically, we ranked the participating centers according to the number of first implantations of CRT-D performed in 2007, which ranged from 1 to 107 (median 12), and for descriptive analysis we divided them into tertiles of increasing procedure volume: low volume (Ͻ10 procedures), medium volume (from 10 to 19), and high volume (Ն20).
Study End Points
In the present analysis, the study database was searched for all device-related adverse events, defined as untoward events resulting from the presence or performance of the implanted system. Specifically, we analyzed anticipated (ie, device replacement for battery depletion) and unanticipated device-related events resulting in surgical intervention for system revision.
The additional long-term risk related to an ICD that also delivers CRT was assessed by comparing the events occurred in CRT-D group and in patients who underwent de novo implantation of singleor dual-chamber ICD systems at the study centers during the same period.
Statistical Analysis
Descriptive statistics are reported as meansϮSD for normally distributed continuous variables, or medians with 25th to 75th percentiles in the case of skewed distribution. Categorical variables are reported as percentages. The rate of events is reported as the number of events observed per patient-year. Survival analysis was performed by means of the Kaplan-Meier method, and the log-rank test was applied to evaluate differences between survival trends (level of significance: Pϭ0.017 after adjustment for multiple testing by Bonferroni correction). For all estimations of time to events, patients were censored at death or at their last follow-up visit.
Hazard ratios (HRs) and their 95% confidence intervals (CIs) were computed by means of Cox regression models, where baseline predictors were considered as fixed covariates and device-related events were considered as time-dependent covariates. After checking for collinearity, we included in the multivariate Cox models any variable with PϽ0.1 on univariate analysis. A P value Ͻ0.05 was considered significant for all tests. All statistical analyses were performed using SPSS software (SPSS Inc, Chicago, IL).
Results
Study Population
From 2004 to 2009, a total of 3865 heart failure patients received a CRT-D and were enrolled at the 117 study centers. After excluding patients with a previous ICD or CRT device, we included in the analysis 3253 patients who underwent successful de novo CRT-D implantation. Baseline clinical variables, echocardiographic parameters, and pharmacological treatment of these patients are summarized in Table 1 .
Data collected on implantation are reported in Table 2 . Implanting physicians at the study centers used different LV lead models in a variety of sizes, polarity configurations, and fixation systems. The majority of leads were deployed in a lateral or posterolateral cardiac vein, and the mean LV pacing threshold was 1.3Ϯ0.8V at 0.5 ms pulse width.
During the same period, 1576 patients underwent de novo implantation of single-(nϭ741) or dual-chamber (nϭ835) ICD at the study centers for primary (1104 patients) or secondary (472 patients) prevention of sudden cardiac death.
Follow-Up
During a median follow-up of 18 months (25th to75th percentiles, 9 to 30), device-related events occurred in 416 CRT-D patients; 483 events resulting in surgical intervention for system revision were reported in 390 patients. Specifically, on excluding patients undergoing only device replacement for battery depletion, 220 events requiring surgical revision occurred in 210 patients. Details of the events occurring during follow-up and resulting in surgical revision are provided in Figure 1 . In addition to these, 16 episodes of incisional infection at the pocket site were effectively treated by means of a conservative approach without system removal, thus yielding a total rate of 1.0 infection per 100 patient-years. Moreover, 22 additional events of LV lead dislodgment were noninvasively managed, and CRT was restored by increasing the pacing output or modifying the LV pacing configuration.
During follow-up, the majority of unanticipated devicerelated events proved to be lead dislodgments, specifically the dislodgment of the LV lead, and device-related infections. The present CRT-D series also included 1985 patients with a right ventricular ICD lead of the Sprint Fidelis family (subject of the advisory issued in October 2007). Thus, we recorded 44 lead failures among patients with Sprint Fidelis (1.5 failures per 100 patient-years), and 7 elective replacements of nonmalfunctioning leads. The actuarial lead failure survival probability was 99.7% at 1 year, 98.5% at 2 years, 96.9% at 3 years, and 94.2% at 4 years. In addition, we reported surgical revisions for 3 failures of different ICD lead models and 4 failures of LV leads.
The Kaplan-Meier estimates of time to first surgical revision, first unanticipated event, and battery depletion were performed for patients with CRT-D and compared to singleand dual-chamber ICDs ( Figure 2 ). Cardiac resynchronization therapy defibrillator systems demonstrated significantly higher rates of all events than single-chamber ICDs, as well as higher rates of surgical revision and battery depletion than dual-chamber ICDs (all PϽ0.001). Specifically, the actuarial rate of battery depletion was 50% in CRT-D and 10% in the single-and 13% in the dual-chamber ICD group at 4 years. Similarly, unanticipated events were reported in 14% of CRT-D patents and 4% of single-and 9% of dual-chamber ICD patients. Kaplan-Meier curves showing survival free from device-related infection and LV lead dislodgment for patients with CRT-D systems are reported in Figure 3 .
Predictors of Device-Related Infections
Clinical parameters and implantation data were evaluated for their predictive value for device-related infections by univariable and multivariable analysis, as reported in Table 3 . No independent predictors of device-related infections were identified among baseline parameters, except for an association with the presence of chronic obstructive pulmonary disease bordering on significance (Pϭ0.050).
Device replacement procedure showed a significant association with the occurrence of infections during follow-up at multivariable analysis (Pϭ0.045), with a rate of devicerelated infections of 0.9 events per 100 patient-years after the first implantation and 1.8 events per 100 patient-years after device replacement procedure during the entire follow-up.
Predictors of Left Ventricular Lead Dislodgements
Although the occurrence of LV lead dislodgements during follow-up was not predicted by any baseline clinical variable, it proved to be significantly related to a longer fluoroscopy Valve disease, n (%) 604 (19) Previous valve surgery, n (%) 175 (5) Previous single-chamber pacemaker, n (%) 60 (2) Previous dual-chamber pacemaker, n (%) 284 (9) Hypertension, n (%) 1533 (47) Diabetes mellitus, n (%) 730 (22) Chronic kidney disease, n (%) 266 (8) COPD, n (%) 400 ( time during implantation and to a higher baseline LV pacing threshold (Table 4) .
Patient Outcome
During follow-up, 167 patients (rate 4.0 per 100 patient-years of follow-up) died or underwent urgent heart transplantation. 
Discussion
Our analysis of the current clinical practice of a large number of Italian centers showed that 4 years after a successful implantation procedure, 50% of patients with a CRT-D system underwent surgical revision for battery depletion and 14% for unanticipated events, such as device-related infections and LV lead dislodgments. For comparison, surgical revision for battery depletion occurred in 10% and 13%, and unanticipated events in 4% and 9%, respectively, of patients who underwent implantation of single-or dual-chamber ICDs.
Recently, Freeman et al 9 examined the relationship between hospital ICD implantation volume and procedural complications in a contemporary population. They showed that patients who have an ICD implanted at a high-volume hospital are less likely to suffer a procedure-related adverse event. However, a weaker volume-outcome relationship was observed for biventricular ICDs than for other ICD types.
Similarly, in the present analysis we were not able to identify any association between procedure volume and the occurrence of complications in the CRT-D practice of several Italian centers despite their extremely variable volume of activity. Among the possible mechanisms that could explain this result, as mentioned by Freeman et al, 9 the possibility exists that only more skilled operators attempted the more complicated biventricular ICD implantations, thus minimizing the variation in outcomes associated with the less complicated device implantations.
Knight et al 10 analyzed CRT-D patients enrolled in the VENTAK CHF/CONTAK CD Biventricular Pacing Study to determine the frequency and causes of intermittent and permanent loss of CRT. They reported that CRT was interrupted in 36% of patients during a mean follow-up of 2.5 years but that most of these patients underwent intervention that enabled the reinstitution of CRT, with the result that only 5% experienced permanent loss of therapy. However, the frequency of complications requiring invasive procedures was not quantified. More recently, Duray and colleagues 11 described the complications that occurred in their 7-year single-center experience of ICD implantation and showed that the incidence of complications was significantly higher in CRT-D than in single-and dual-chamber ICD, accounting for an annual incidence of surgical revision of Ϸ12%.
Our experience constitutes the first large analysis of the frequency and nature of long-term device-related events after CRT-D implantation in current clinical practice. In Europe, and especially in Italy, CRT-D use is rising faster than the use of any of the other devices indicated for heart failure treatment. 13 In the light of the recent extension of European CRT recommendations to mildly symptomatic patients, 5 further growth can be expected. Recently, attention has been drawn to the number of ICD recipients who may not benefit from the device but are still exposed to procedural and device-related complications, raising the question of whether current complications of ICD therapy have been underestimated and the benefits overestimated. 14 As shown in the present analysis, the risk of repeat invasive procedure is higher for CRT-D recipients than for patients who undergo implantation of single-or dual-chamber ICDs. Nevertheless, when the defibrillation device also delivers CRT, further reducing the risk of death 15 and providing the well described benefits in terms of improved quality of life, functional capacity, exercise performance, and reduction in heart failure events, the risk-benefit balance becomes more favorable.
Device-Related Infections
During long-term follow-up, device-related infections occurred at a steady rate of 1.0 events per 100 patient-years. Infection of implantable cardiac devices remains a serious problem despite improvements in implantation techniques. Previous studies quantified the incidence of infections in cardiac device recipients in the early postimplantation phase. 16 -18 On measuring the frequency of major complications on implantation among Medicare beneficiaries with ICD, Reynolds et al 16 reported an infection rate of 0.7% in CRT-D recipients. The multicenter Prospective Evaluation of Pacemaker Lead Endocarditis (PEOPLE) study 17 examined the 1-year incidence of infectious complications after the implantation of antiarrhythmic devices; however, no CRT-D were included in the study. In their analysis, these investigators identified some risk factors of infection (eg, fever on implantation, use of temporary pacing before the procedure, and pulse generator replacement) and confirmed the efficacy of antibiotic prophylaxis on implantation. In our long-term analysis of a large population of CRT-D recipients, we did not find independent predictors of infections among baseline clinical characteristics; thus, we did not identify subgroups of patients more at risk of this kind of complication. Nonetheless, we observed a significantly higher risk of infections after device replacement procedures. In our study, the majority of device infections were successfully managed through system removal. No prospective studies have examined the treatment of infections with antibiotics versus device extraction. Most previously published studies, however, have shown unacceptably high failure rates for conservative treatment without hardware removal. 19 -21 Because of the difficulty of differentiating between local infection and infective endocarditis in device recipients, the recently published European Society of Cardiology guidelines on the treatment of infective endocarditis 22 recommend full system removal even when extension of the infection to the electrode leads is only suspected.
Left Ventricular Lead Dislodgements
Left ventricular lead dislodgements requiring surgical revision occurred at a rate of 2.3 events per 100 patient-years, and, on Kaplan-Meier analysis, seemed to be more frequent during the first 6 months after implantation of the lead. The analysis of predictors also revealed a close relationship with the implantation procedure. Indeed, longer fluoroscopy time and higher baseline LV pacing threshold, both signs of a challenging implantation procedure, were associated with LV lead dislodgments during follow-up. It had previously been demonstrated that patients with higher LV pacing thresholds also showed marked fluctuations in threshold and were at risk of inconsistent resynchronization therapy during follow-up. 23 This was ascribed to suboptimal stability and contact of the LV electrode with the epicardium. Our findings confirm this hypothesis and demonstrate an association between LV threshold and lead stability. Nevertheless, our centers showed an overall good performance on implantation in terms of procedure times, coronary vein achieved for permanent pacing, and mean pacing parameters. This may be also ascribed to the wide range of available LV pacing leads.
Lead Malfunctions
The present series also included patients with ICD leads under safety advisory; consequently, surgical revisions for lead malfunction or elective replacement contributed to the total number of device-related events reported. The failure rate of Sprint Fidelis leads was 1.5 per 100 patient-years, and was comparable to that reported by Medtronic in its semiannually updated Product Performance Report. 24 On the contrary, Hauser et al reported more frequent lead failures (2.8 per 100 patient-years) in their recent independent multicenter study. 25 This discrepancy may be due to our shorter observation period and, most probably, to the fact that our population did not include representative samples of high-risk groups 25 : young patients, women, individuals with hypertrophic cardiomyopathy, and patients with arrhythmogenic right ventricular dysplasia or channelopathies.
Device Longevity
In agreement with previous reports, 12, 26 device replacements for battery depletion started to occur after 3 years of follow-up and involved 50% of CRT-D patients after 4 years at Kaplan-Meier analysis. Previous data from a large US registry showed that 53% of normally performing ICDs and, specifically, only 4% of CRT-D were in service 4 years after implantation. 27 In our series, battery depletion represented the main cause of earlier surgical revision in patients with CRT-D. Indeed, it has been shown that CRT-D are the most demanding antiarrhythmic devices in terms of battery consumption because of the need for continuous biventricular pacing, although device longevity may differ significantly among manufacturers 12, 26 and modern algorithms for pacing output reduction have been demonstrated to improve longevity. 28 Nevertheless, the risk of earlier surgical revision for battery depletion in CRT-D should be considered not only per se, but also in relationship with the observed higher risk of infection following replacement. Moreover, system revisions for battery depletion represent an important source of incremental costs. Indeed, extension of system longevity was shown to significantly improve cost-effectiveness estimates. 29 Narrowing the mismatch between the service life of ICDs and patient longevity (ie, providing an ICD that lasts a lifetime) 30 must represent the goal for technological research. This result should be more achievable for CRT-D systems because of the short life expectancy of their recipients, and could be obtained not only by enhancing battery capacity but also by using algorithms for pacing output minimization, as well as through progress in lead technology to ensure good electric performance.
Patient Outcome
In our experience, device-related events necessitating surgical revision or involving specific complications, such as infections or lead dislodgments, were documented during longterm follow-up. These events proved not to be associated with a worse clinical outcome, as shown by the comparable risks of death in patients with and without device-related events, confirming findings from a recent CRT trial. 15 This differs from the case of direct implantation-related complications and major perioperative events, which have been associated with an increased risk of death. 6 Nonetheless, in addition to possible clinical consequences, the occurrence of complications during follow-up clearly represents a source of incremental costs to the healthcare system, as already demonstrated with regard to early complications, which have proved to be associated with significant increases in length of hospitalization and total hospital costs. 16 Therefore, efforts to reduce these events could have significant financial as well as clinical benefits.
Limitations
As already mentioned, only successful implantations were included in the study, and information on periprocedural complications and intraoperative death were not reported. However, a success rate of 93.7% for CRT-D, with periimplantation deaths occurring in 0.5% of patients, was previously reported in a large meta-analysis of published CRT experiences. 1 Furthermore, the present study described a large experience of implantation and long-term management of CRT-D produced by a single manufacturer. Our findings might therefore not be applicable to generators and leads from other manufacturers. However, although the device longevity or the lead malfunctions strictly depend not only on the manufacturer, but also on the specific device family, findings on events such as device-related infections and lead dislodgments are more generally applicable.
The clinical management of the patients in this analysis (ie, the assessment of implantation indications, pharmacological treatment, and CRT-D programming and the management of possible complications) was not standardized, and was performed according to each center's clinical practice. This aspect may have had an impact on the present findings. However, our study provided insights about the current general practice that could not be obtained with randomized controlled trials.
Conclusions
In summary, our analysis of the current clinical practice of a large number of Italian centers showed that long-term devicerelated events were more frequent in CRT-D than in single-or dual-chamber ICD, as indeed was expected, given the complexity of the implanted device, 6 and that they were frequently managed by surgical intervention for system revision. However, a worse clinical outcome is not to be associated with these events.
During implantation and follow-up, every effort should be made to address all safety issues associated with cardiac device use, and the continuous study of new preventative strategies is warranted. Moreover, our findings seem to suggest the need for the physician to correctly inform the patient at the time of implantation not only about possible procedural risks, but also about the risk of surgical revisions during follow-up.
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